LYTIR

Company · AGIO

Agios Pharmaceuticals, Inc.

Name as listed on its exchange; filed with the SEC as AGIOS PHARMACEUTICALS, INC.

Nasdaq's symbol directory lists AGIO on Nasdaq as “Agios Pharmaceuticals, Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders sold on 5 occasions ($1.4M); 3 planned-sale notices; 3 filings by holders of 5% or more; 3 congressional trade disclosures; 1 company report (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $1.4M in total.Jul: Insider sales $151KAug: Insider sales $914KOct: Insider sales $371KDecJanFebMarAprMayJunJulAugSepOctNov$914K
Insider purchases above the line: $0Insider sales below: $1.4M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Sarah Gheuens, Chief Medical Officer sold on 5 days all under a 10b5-1 plan latest Oct 26, 2026 sold $1.4M
Every trade (5)
  1. SELLSarah Gheuens, Chief Medical Officer sold Oct 26, 2026 7,866 shares 10b5-1 plan (scheduled) filing $296K
  2. SELLSarah Gheuens, Chief Medical Officer sold Oct 22, 2026 500 shares 10b5-1 plan (scheduled) filing $19K
  3. SELLSarah Gheuens, Chief Medical Officer sold Oct 21, 2026 1,489 shares 10b5-1 plan (scheduled) filing $56K
  4. SELLSarah Gheuens, Chief Medical Officer sold Aug 4, 2026 30,000 shares 10b5-1 plan (scheduled) filing $914K
  5. SELLSarah Gheuens, Chief Medical Officer sold Jul 1, 2026 4,007 shares 10b5-1 plan (scheduled) filing $151K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. SARAH GHEUENS filed Oct 26, 2026 Officer 7,866 shares planned sale date 10/26/2026 filing $296K
  2. SARAH GHEUENS filed Oct 22, 2026 Officer 500 shares planned sale date 10/22/2026 filing $19K
  3. SARAH GHEUENS filed Oct 21, 2026 Officer 1,489 shares planned sale date 10/21/2026 filing $56K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Morgan Stanley filed Nov 13, 2026 Schedule 13G passive filing 5.7%
  2. Farallon Capital Management, L.L.C. filed Aug 3, 2026 Schedule 13G/A passive filing 9.9%
  3. D. E. SHAW & CO, L.P. filed Jul 2, 2026 Schedule 13G passive filing 5.1%

Congress · STOCK Act

The Althing

Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.

  1. Gilbert Cisneros (D-CA31): Purchase Aug 20, 2026 reported Sep 10, 2026 one of 58 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  2. Gilbert Cisneros (D-CA31): Purchase Mar 3, 2026 reported Apr 7, 2026 one of 141 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  3. Gilbert Cisneros (D-CA31): Purchase Dec 11, 2025 reported Jan 12, 2026 one of 121 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 5, 2026

Lobbying · Senate LDA reports

Lobbying filed

2 quarterly lobbying reports for 2026 naming Agios Pharmaceuticals, Inc. as the client: 2 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.

  1. JEFFREY J. KIMBELL & ASSOCIATES, INC. Q2 2026 filing $10K
  2. JEFFREY J. KIMBELL & ASSOCIATES, INC. Q1 2026 filing $10K

Federal contracts · USAspending.gov

Federal contracts

1 contract award first obligated in the last 12 months to the company or a subsidiary it lists in its 10-K, $73K in total obligated as USAspending.gov lists each award when Lytir last read it. Largest first.

  1. Department of Veterans Affairs Jul 14, 2026 to AGIOS PHARMACEUTICALS, INC. award $73K

Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, USAspending.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.